RT Journal Article
T1 Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?
A1 Riedel, Rodrigo N
A1 Pérez-Pérez, Antonio
A1 Sánchez-Margalet, Víctor
A1 Varone, Cecilia L
A1 Maymó, Julieta L
K1 Amnion
K1 COVID-19
K1 Human amniotic epithelial cells
K1 Human amniotic mesenchymal stromal cells
K1 Mesenchymal stem cells
K1 SARS-CoV-2
K1 Stem cell therapy
K1 Stem cells
AB A new coronavirus respiratory disease (COVID-19) caused by the SARS-CoV-2 virus, surprised the entire world, producing social, economic, and health problems. The COVID-19 triggers a lung infection with a multiple proinflammatory cytokine storm in severe patients. Without effective and safe treatments, COVID-19 has killed thousands of people, becoming a pandemic. Stem cells have been suggested as a therapy for lung-related diseases. In particular, mesenchymal stem cells (MSCs) have been successfully tested in some clinical trials in patients with COVID-19. The encouraging results positioned MSCs as a possible cell therapy for COVID-19. The amniotic membrane from the human placenta at term is a valuable stem cell source, including human amniotic epithelial cells (hAECs) and human mesenchymal stromal cells (hAMSCs). Interestingly, amnion cells have immunoregulatory, regenerative, and anti-inflammatory properties. Moreover, hAECs and hAMSCs have been used both in preclinical studies and in clinical trials against respiratory diseases. They have reduced the inflammatory response and restored the pulmonary tissue architecture in lung injury in vivo models. Here, we review the existing data about the stem cells use for COVID-19 treatment, including the ongoing clinical trials. We also consider the non-cellular therapies that are being applied. Finally, we discuss the human amniotic membrane cells use in patients who suffer from immune/inflammatory lung diseases and hypothesize their possible use as a successful treatment against COVID-19.
YR 2021
FD 2021-03-01
LK http://hdl.handle.net/10668/17258
UL http://hdl.handle.net/10668/17258
LA en
DS RISalud
RD Apr 7, 2025